Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 7/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | C1R | P00736 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13223614 | 0.96 | KEAP1 (0.41) | KEAP1NFE2L2LMNATAS2R14MAPT | |
| SCHEMBL9350381 | 0.95 | KEAP1 (0.43) | KEAP1NFE2L2LMNATAS2R14MAPT | |
| SCHEMBL9348982 | 0.93 | KEAP1 (0.41) | KEAP1NFE2L2LMNATAS2R14MAPT | |
| SCHEMBL30180827 | 0.92 | KEAP1 (0.43) | KEAP1NFE2L2LMNATAS2R14MAPT | |
| SCHEMBL17260208 | 0.92 | KEAP1 (0.43) | KEAP1NFE2L2LMNATAS2R14MAPT | |
| SCHEMBL6363184 | 0.92 | KEAP1 (0.38) | KEAP1NFE2L2LMNATAS2R14C1R | |
| SCHEMBL18118852 | 0.92 | RAB9A (0.42) | KEAP1NFE2L2LMNAMAPTMEN1 | |
| SCHEMBL17268342 | 0.90 | MEN1 (0.39) | KEAP1NFE2L2LMNATAS2R14MEN1 | |
| SCHEMBL18114368 | 0.90 | KEAP1 (0.44) | KEAP1NFE2L2LMNATAS2R14MEN1 | |
| SCHEMBL2329207 | 0.88 | KEAP1 (0.40) | KEAP1NFE2L2LMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170336416-A1 | COMPOSITIONS FOR ENHANCING CHEMILUMINESCENCE AND METHODS OF USING THE SAME | ABBOTT LABORATORIES | 2017-11-23 | — | — | US | claimed |
| US-20150330986-A1 | COMPOSITIONS FOR ENHANCING CHEMILUMINESCENCE AND METHODS OF USING THE SAME | ABBOTT LAB (US) | 2015-11-19 | — | — | US | claimed |
| EP-3523640-B1 | DEVICES FOR SAMPLE ANALYSIS | ABBOTT LAB (US) | 2023-01-18 | — | — | EP | disclosed |
| EP-3523640-B1 | DEVICES FOR SAMPLE ANALYSIS | ABBOTT LAB (US) | 2023-01-18 | — | — | EP | disclosed |
| US-20210325334-A1 | Devices and Methods for Sample Analysis | ABBOTT LABORATORIES | 2021-10-21 | — | — | US | disclosed |
| EP-3839507-A1 | DEVICES AND METHODS FOR SAMPLE ANALYSIS | Abbott Laboratories (US) | 2021-06-23 | — | — | EP | disclosed |
| US-11022598-B2 | Devices and methods for sample analysis | ABBOTT LABORATORIES (US) | 2021-06-01 | — | — | US | disclosed |
| US-11016053-B2 | Devices and methods for sample analysis | ABBOTT LABORATORIES (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3278108-B1 | DEVICES AND METHODS FOR SAMPLE ANALYSIS | ABBOTT LAB (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3278108-B1 | DEVICES AND METHODS FOR SAMPLE ANALYSIS | ABBOTT LAB (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20200256843-A1 | DEVICES AND METHODS FOR SAMPLE ANALYSIS | ABBOTT LABORATORIES (US) | 2020-08-13 | — | — | US | disclosed |
| US-20080206788-A1 | Reagents and methods for the detection and quantification of vancomycin in biological fluids | ADAMCZYK MACIEJ | 2008-08-28 | — | — | US | disclosed |
| US-7319041-B2 | Applications of acridinium compounds and derivatives in homogeneous assays | SIEMENS MEDICAL SOLUTIONS DIAGNOSTIC (US) | 2008-01-15 | — | — | US | disclosed |
| EP-1121599-B1 | DETECTION AND QUANTIFICATION OF VANCOMYCIN IN BIOLOGICAL FLUIDS | ABBOTT LAB (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040209318-A1 | Reagents and methods for the detection and quantification of vancomycin in bilogical fluids | ADAMCZYK MACIEJ (US) | 2004-10-21 | — | — | US | disclosed |
| US-6797479-B2 | IMMUNOASSAY REAGENTS, METHODS AND TEST KITS; ANTIBODY REAGENT PRODUCED WITH IMMUNOGEN-CONJUGATED VANCOMYCIN, A LABELED VANCOMYCIN REAGENT WHICH IS CAPABLE OR DISPLACING THE BINDING OF THE ANTIBODY TO VANCOMYCIN, AND STABLE CALIBRATOR | ABBOTT LABORATORIES | 2004-09-28 | — | — | US | disclosed |
| US-20020009708-A1 | REAGENTS AND METHODS FOR THE DETECTION AND QUANTIFICATION OF VANCOMYCIN IN BIOLOGICAL FLUIDS | ABBOTT LABORATORIES | 2002-01-24 | — | — | US | disclosed |
| EP-1121599-A1 | DETECTION AND QUANTIFICATION OF VANCOMYCIN IN BIOLOGICAL FLUIDS | ABBOTT LABORATORIES (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000023806-A9 | DETECTION AND QUANTIFICATION OF VANCOMYCIN IN BIOLOGICAL FLUIDS | ABBOTT LAB (US) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000023806-A1 | DETECTION AND QUANTIFICATION OF VANCOMYCIN IN BIOLOGICAL FLUIDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150330986-A1 | COMPOSITIONS FOR ENHANCING CHEMILUMINESCENCE AND METHODS OF USING THE SAME | APOB, MPO, LPO | KEAP1 1733/4885NFE2L2 885/4885LMNA 813/4885 |
| US-20170336416-A1 | COMPOSITIONS FOR ENHANCING CHEMILUMINESCENCE AND METHODS OF USING THE SAME | APOB, MPO, LPO | KEAP1 1733/4885NFE2L2 885/4885LMNA 813/4885 |
| US-20080206788-A1 | Reagents and methods for the detection and quantification of vancomycin in biological fluids | SERPINA6, CD4, VSIR | KEAP1 2298/4885NFE2L2 4778/4885LMNA 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.